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Abstract
It has been demonstrated that patients enrolled in clinical trials frequently have a large degree of
variation in their baseline risk for the outcome of interest. Thus, some have suggested that clinical
trial results should routinely be stratified by outcome risk using risk models, since the summary
results may otherwise be misleading. However, variation in competing risk is another dimension of
risk heterogeneity that may also underlie treatment effect heterogeneity. Understanding the effects
of competing risk heterogeneity may be especially important for pragmatic comparative
effectiveness trials, which seek to include traditionally excluded patients, such as the elderly or
complex patients with multiple comorbidities. Indeed, the observed effect of an intervention is
dependent on the ratio of outcome risk to competing risk, and these risks – which may or may not
be correlated – may vary considerably in patients enrolled in a trial. Further, the effects of
competing risk on treatment effect heterogeneity can be amplified by even a small degree of
treatment related harm. Stratification of trial results along both the competing and the outcome
risk dimensions may be necessary if pragmatic comparative effectiveness trials are to provide the
clinically useful information their advocates intend.
Introduction
Recent commentaries have highlighted several fundamen-
tal limitations of clinical trials in providing an evidence-
base for medical practice. It has been pointed out that
many patients seen in routine clinical practice, particu-
larly older and complex patients with multiple comorbid
conditions, are excluded from clinical trials [1,2]. To
address this, there has been a call for pragmatic compara-
tive effectiveness trials with broader inclusion criteria,
with the goal of enrolling a diverse patient population
more representative of patients seen in routine clinical
practice [3]. However, other commentaries have high-
lighted another limitation in clinical trials: substantial
treatment-effect heterogeneity within trials often makes
the overall summary result difficult to interpret and apply
[4-7]. Enrolling a greater diversity of patients will increase
this within trial heterogeneity. Thus, while some argue for
broader inclusion criteria to make results more "general-
izable", increasing patient heterogeneity yields overall
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misleading.
While a consensus has yet to fully emerge on how best to
deal with treatment-effect heterogeneity, the limitations
of conventional subgroup analyses are well-appreciated.
Since patients have multiple attributes that might affect
the risks and benefits of an intervention – they are male or
female, young or old, with or without diabetes, have a
high or low blood pressure, blood count, cholesterol, uri-
nary protein excretion, ejection fraction, etc. – it is statisti-
cally impractical to consider each potentially important
attribute in a one at a time manner [6,7]. It has therefore
been suggested that patient characteristic be combined by
risk models that describe fundamental dimensions of risk
likely to underpin treatment-effect heterogeneity [6,9-11].
Prior work has demonstrated that variation in outcome-
risk (i.e. a patient's baseline risk of having the outcome of
interest) is a fundamental determinant of the opportunity
for treatment benefit, and of the risk-benefit trade-offs
when there is any treatment-related harm [6,9-11].
Because variation in outcome-risk among patients
enrolled in clinical trials is ubiquitous, frequently large
and typically skewed, a relatively small subgroup of high-
risk patients often account for most trial outcomes and
have a disproportionate influence on overall trial results
[12]. Indeed, the summary result of a clinical trial might
not even accurately reflect the tested intervention's treat-
ment-effect in a typical patient within the trial [6,12].
Because of this, and because outcome-risk variation can
often be well-described with a simple multivariate risk
model, routine stratification of trial results by outcome-
risk has been recommended [6,9-11,13]. In addition to
outcome-risk, it is also recognized that, for treatments
with serious and non-rare adverse effects (e.g. surgery or
fibrinolytic therapy), individual patient variation in vul-
nerability to treatment-related harm can give rise to
important treatment-effect heterogeneity; thus, it may in
some circumstances be appropriate to stratify patients
based on their risk of treatment-related harm [6,9,14,15].
However, another dimension of risk heterogeneity from
which clinically significant differences in treatment-effect
may emerge is relatively neglected and may be of particu-
lar importance for comparative effectiveness trials: varia-
tion in competing risk. Competing risk is the risk of an
event that interferes with the probability of experiencing
the disease-specific outcome of interest [16]. It is not
merely a statistical issue affecting Kaplan-Meier [16] or
sample size [17] estimates, but a clinical issue especially
important when considering treatments in older or com-
plex patients with multiple comorbidities for whom com-
peting events may limit the likelihood of treatment
benefit. This paper considers how – even for treatments
with uniform treatment efficacy-understanding the com-
plex interplay between baseline risk, treatment-related
harm and competing risk is important in making good
individual-patient recommendations and decisions, and
how analyzing the effects of competing and outcome risks
in clinical trials – normally obscured by overall trial
results – may better inform clinical decision-making.
Discussion
When Competing Risk is Uncorrelated with Outcome-Risk
To illustrate the interplay between outcome-risk and com-
peting risk, consider the use of adjuvant chemotherapy for
breast cancer. Adjuvant chemotherapy reduces the risk of
breast cancer death in both node positive and node nega-
tive cancers [18]. Since the treatment carries a non-trivial
risk of serious complications, evidence-based guidelines
often strongly recommend that the patient's risk of cancer
recurrence and death (based upon cancer grade and stage)
play an important role in determining who should receive
chemotherapy [19]. However, breast cancer frequently
behaves like a chronic disease, with events occurring over
a decade or more, and there is tremendous variation in the
risk of both breast cancer and non-breast cancer death
across the breast cancer population.
Table 1 shows how the benefit of chemotherapy will vary
according to both the baseline risk from the cancer itself
and the degree of competing risk for mortality, even
Table 1: Interactions between baseline risk, treatment-related harm (Rx-harm) and competing risk (CR) when chemotherapy reduces 
breast cancer mortality by 15%.
Risk of Breast CA Death No Rx-harm or CR Rx-harm (1.5% absolute rate) but no CR Rx-harm & CR is:
Low (10%) Moderate (25%) High (50%)
(10-yr CA Mortality) Absolute Risk Reduction/Number Needed to Treat
Low (10%) .015/67 0/8 -.002/-667§ -.004/-267§ -.007/-133§
Moderate (25%) .038/27 .023/44 .019/53 .013/76 .004/267
High (50%) .075/13 .060/17 .053/19 .041/24 .022/44
§ The negative sign denotes instances in which chemotherapy does net harm, meaning that the statistics represent absolute risk increase and 
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patients (relative risk reduction = 15%) and a constant
absolute rate of serious treatment-related harm (15 events
over 10 years per 1000 people treated). Based on these
assumptions, and estimated survival rates for stages 1, 2
and 3 breast cancer [20], consistent with our previous
work [6,9,10], those who are at very high risk of dying
from the disease usually benefit substantially despite the
risks of treatment-related harm, and not surprisingly, even
when there is substantial competing risk. This is because
when the baseline breast cancer risk is high the disease-
specific risk overwhelms competing risks from comorbid
illnesses, and an efficacious treatment produces a large
amount of absolute benefit, far outweighing the small risk
of treatment-related harm (see Table 1).
For patients with a more favorable prognosis, however,
the absolute amount of benefit of the same treatment is
much more modest, such that treatment-related harm and
competing risk can greatly attenuate or reverse the net
benefits of treatment. For example, a patient with a non-
trivial 10% percent breast cancer mortality risk would
appear to be a good candidate in the absence of other risks
(number needed to treat [NNT] = 67); however, a small
treatment-related risk would nullify their potential benefit
and the presence of relatively modest competing risks
would cause the treatment to result in net harm. Even for
patients with a substantial 25% risk of breast cancer death
in the absence of competing risks, a high rate of compet-
ing risk results in a greatly attenuated treatment-effect; the
NNT increases from 44 (with no competing risks) to 267
(with a 50% 10-year competing risk of mortality). If
patients with high competing risk also had twice the nor-
mal risk of treatment-related harm (and the risk of treat-
ment-related harm is often influence by comorbid illness)
then chemotherapy would result in net harm (number
needed to harm [NNH] = 91).
Note that a 10-year competing risk of mortality of 50% is
not extreme for breast cancer. Approximately a third of
breast cancer patients are over the age of 70. The 10-year
risk of competing mortality would be approximately 50%
for a 70 year old at only slightly higher than average risk
[21]. Indeed, a median age breast cancer patient (age 61)
with asymptomatic class I CHF would also have approxi-
mately a 50% 10-year risk of competing mortality [22].
Table 1 demonstrates that the overall measured effective-
ness of adjuvant chemotherapy in a clinical trial depends
on the distribution of the competing and outcome risks of
trial enrollees. By excluding older patient or those with
comorbidities, [23,24] oncology trials enhance their like-
lihood of detecting treatment benefit, but their results are
directly applicable only to patients with low competing
risks. While enrolling older patients, and patients with
multiple comorbidities would attenuate the treatment-
effect in the summary results, it would still not provide the
clinically useful knowledge about who to treat unless
analyses included risk-based stratification, incorporating
both competing and outcome risk.
When Competing Risk is Correlated with Outcome-Risk
While the presence or absence of comorbidities should
not substantially alter the likelihood of a more aggressive
versus a more indolent form of cancer, in many circum-
stances, competing risk can be highly correlated with the
disease-specific outcome-risk. For example, an implanta-
ble cardiac defibrillator (ICD) would be of most benefit in
patients with a high risk for sudden cardiac death (SCD)
but little risk for death from other causes [25], since
implanting these devices (costly and not risk-free) in
patients destined to die from non-arrhythmic causes is
highly undesirable. However, the criteria used to identify
eligible patients at high risk for sudden cardiac death
(SCD), namely a left ventricular ejection fraction of 35%
or less, also identifies patients at risk of cardiac death from
pump failure [26,27]. Separating these risks has proven
difficult, as factors that predict mortality from SCD also
usually predict non-SCD mortality [28].
The Seattle Heart Failure Model (SHFM), developed on a
database of pooled clinical trials consisting of 10,538
ambulatory patients with heart failure [29], predicts total
mortality in patients with congestive heart failure based
on easily obtainable clinical variables. Both SCD and
pump failure death substantially increase across risk strata
[30]. However, the ratio between SCD and pump failure
death dramatically decrease in higher risk compared to
lower risk patients; low risk patients with risk scores of
zero have roughly a 7 to 1 SCD to pump failure death
ratio, while this ratio was 1 to 2 in patients with risk scores
of 4 [30].
As Figure 1 demonstrates, these different ratios across risk
strata can have important effects on the measured effec-
tiveness of ICDs. As mortality risk increases, the relative
risk reduction of ICDs dramatically decreases. This is
because the relative risk reduction is inversely related to
the ratio of preventable disease-specific (SCD) to non-pre-
ventable competing risk of mortality. More surprisingly,
the absolute risk reduction across risk strata is described
by a non-linear, inverted U-shaped function (Figure 1b).
Intermediate risk patients are most likely to benefit, as low
risk patients are unlikely to have an arrhythmic death even
in the absence of treatment while benefit in the highest
risk group is limited by the high rate of non-arrhythmic
death. Folding in treatment-related harm could further
amplify this treatment-effect heterogeneity, particularly if
sicker patients were more prone to ICD-induced adverse
events.Page 3 of 6
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with a risk-stratified analysis of the Multicenter Automatic
Defibrillator Implantation Trial (MADIT)-II [31,32].
While overall MADIT-II found a 31% reduction in all-
cause two-year mortality associated with the ICD [31], the
ICD did not appear to reduce all-cause mortality in either
the very low risk group (defined as no more than 1 of mul-
tiple risk factors) or a very high risk group of patients
(defined as those with blood urea nitrogen ≥ 50 mg/dL or
serum creatinine ≥ 2.5 mg/dL) [32]. While the intermedi-
ate mortality risk group may represent the "sweet spot" for
ICD therapy, more efficient targeting of these devices
could presumably be achieved if risk factors for SCD that
do not predict pump failure could be identified. Again,
summary trial results would be quite dependent on the
risk profile of the enrolled patients, and may be mislead-
ing in some circumstances.
Summary
As seen in the clinical conditions above, variation in com-
peting risk can cause variation in treatment-effect. Even
for treatments with a constant efficacy, the apparent rela-
tive risk reduction of an intervention is directly related to
the ratio between disease-specific and competing risk.
When these two risk dimensions are correlated, increasing
outcome-risk may not uniformly lead to increasing bene-
fit – particularly when the primary outcome is a combina-
tion of disease-specific and competing events. Even when
outcome and competing risks are not correlated, under-
standing how to treat individual patients can depend on
the interplay between competing and outcome risks, and
these effects can be greatly amplified by even small
amounts of treatment-related harm, especially when
those with higher competing risk are also at greater risk of
harm from treatment. Calls for large simple clinical trials
[33] with broad inclusion criteria, including older or com-
plex patients, designed to provide results generalizable to
"real-world" patients [3], have generally ignored the fact
that reporting a summary treatment-effect based on the
arithmetic mean across all patients may at times be mis-
leading. The application of the results of meta-analysis
without a careful consideration of clinical heterogeneity is
also problematic [34]. Since treatment benefit depends on
the ratio between competing and outcome risks, it may be
necessary to stratify these real world effectiveness trials
along these two important risk dimensions, as in Table 1,
or to account for these risks using appropriate multivaria-
ble models.
Some might point out that thoughtful and experienced
clinicians attempt to do this in clinical practice, such that
overall clinical trial results can still be customized at the
bedside. Doctors specializing in prostate cancer, for exam-
ple, are known to apply the so-called 10-year rule [35], an
implicit assessment based on age and co-morbidity,
whereby aggressive therapy might be offered to patients
Relative and Absolute Benefits for Implantable Cardiac Defibrillators (ICDs) Stratified by Total Mortality RiskFigure 1
Relative and Absolute Benefits for Implantable Cardiac Defibrillators (ICDs) Stratified by Total Mortality Risk: 
These graphs show the relative (A) and absolute (B) benefit for ICDs assuming that the devices are 75% effective in preventing 
sudden cardiac death (SCD) but not at all effective in preventing pump failure. The risk ratio of SCD to pump failure death was 
empirically observed [30]. Note that both relative risk reduction decreases monotonically. Absolute risk reduction demon-
strates a U-shaped benefit; benefit is low in low risk groups whose risk of SCD is low and in high risk groups who are suffer 
pump failure.Page 4 of 6
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in general (and oncologists specifically) are prognostically
inaccurate and systematically over-optimistic, when esti-
mating overall life expectancy [36,37]. In addition to
being inaccurate, implicit clinical judgment is an inade-
quate basis for clinical practice in an era where decisions
are expected to conform to guidelines and will be evalu-
ated based on performance measures. While tools which
help formally assess comorbidities and competing risks
may be helpful [38], considering and comparing patient-
specific competing risks to patient-specific disease-specific
risks adds a dimension of complexity likely to render sim-
ple bedside heuristics inadequate since these may be
determined by different or similar factors, and particularly
where the time course for benefits and harms of therapies
can vary. Further, when results of clinical trials themselves
are aggregated across patients with greatly varying disease-
specific and competing risks, the underlying treatment-
effect that should be incorporated in to any decisional
framework at the bedside may be totally obscure.
Conclusion
In order to build an evidence-base that can support guide-
lines for patients who have multiple diseases simultane-
ously, relaxing clinical trial eligibility criteria to include
older and complex patient must be accompanied by anal-
yses that examine how a treatment's net benefit varies by
an individual's disease-specific risk, chance of treatment-
related harm, and competing risks. Research is needed to
develop and test reliable ways to capture competing risk
for different conditions [35,39], to develop sound meth-
odologies to examine treatment-effects across multiple
dimensions of risk, to develop a consensus to standardize
analytic approaches and to identify which circumstances
and clinical conditions these more complex analytic
approaches might be justified and necessary.
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